+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 40Years +
All Genders
Healthy Volunteers
ID06874842

Phase 1 Study of LYB004 Recombinant Zoster Vaccine Safety and Immune Response in Adults Aged 40 and Older

Led by Guangzhou Patronus Biotech Co., Ltd. · Updated on 2025-04-01

92

Participants Needed

1

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase 1 clinical trial in China to evaluate the safety and immune response of the Recombinant Zoster Vaccine, LYB004, in adults aged 40 years and older. The study aims to compare different doses of LYB004 and a positive control vaccine, Shingrix, to better understand how the vaccine works in this population. The trial includes six groups of participants stratified by age and dose level. Participants will receive two doses of either LYB004 at low or high antigen and adjuvant levels, Shingrix, or a placebo, given as intramuscular injections on Day 0 and Day 60. The study uses a randomized, observer-blinded, dose escalation design with sentinel participants for close safety monitoring. Participants will attend scheduled visits for vaccinations and follow-up safety assessments including monitoring for immediate and delayed adverse events, laboratory tests, and immune response measurements. Researchers will evaluate antibody levels and cell-mediated immunity at multiple time points up to 12 months after the second vaccination. The total participation duration extends through this follow-up period to assess both safety and immune responses comprehensively.

CONDITIONS

Brief Title

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Research Team

R

Renfeng Fan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here